PF-06823859

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Dermatomyositis: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2030-07-29.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Dermatomyositis
NCT06698796 · Pfizer
2025-01-22 – 2031-07-29 · Dermatomyositis, Polymyositis
What this study did
Phase 2 (3)
Dermatomyositis
NCT05192200 · Pfizer
2021-12-20 – 2023-11-20 · Dermatomyositis
What this study did
NCT03181893 · Pfizer
2018-01-23 – 2022-11-28 · Dermatomyositis
What this study did
Other / comorbidity
NCT05879718 · Pfizer
2023-07-07 – 2025-11-18 · Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
What this study did
Phase 1 (3)
Other / comorbidity
NCT05257798 · Pfizer
2022-02-28 – 2023-03-21 · Healthy
What this study did
NCT02766621 · Pfizer
2016-05-27 – 2017-09-26 · Healthy
What this study did

Competitive landscape

This drug's own stage for Dermatomyositis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-06823859: this drugPhase 3Monoclonal antibodyInterferon beta (IFN-beta)not yet gradedNo reviewed efficacy summary in this indication
Brepocitinib (Lisraya)ApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Descartes-08Phase 1/2Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PF-06823859 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
July 2030 (1)
Phase 3DermatomyositisRecruiting
Est. primary completion 2030-07-29 · NCT05895786 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 3DermatomyositisRecruiting
Est. primary completion 2031-07-29 · NCT06698796 · CT.gov ↗
What to watch

See the full readout calendar ↗